WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2014185704) ANTIBODY SPECIFICALLY BINDING TO HER2
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2014/185704    International Application No.:    PCT/KR2014/004317
Publication Date: 20.11.2014 International Filing Date: 14.05.2014
IPC:
C07K 16/28 (2006.01), C12N 15/13 (2006.01), A61K 39/395 (2006.01), A61P 35/00 (2006.01)
Applicants: ABCLON INC. [KR/KR]; Suite 1401, Suite 1304, ACE Twin Tower 285, Digital-ro Guro-gu Seoul 152-779 (KR)
Inventors: LEE, Jong-Seo; (KR).
KIM, Kyu-Tae; (KR).
LEE, Young-Ha; (KR).
LEE, Sook-Yeon; (KR).
HWANG, In-Sik; (KR).
KO, Bong-Kook; (KR)
Agent: YANG, Boo-Hyun; Suite 301, Chundong Building, 1992, Namboosunhwan-ro Gwanak-gu Seoul 151-832 (KR)
Priority Data:
10-2013-0055912 16.05.2013 KR
Title (EN) ANTIBODY SPECIFICALLY BINDING TO HER2
(FR) ANTICORPS SE LIANT SPÉCIFIQUEMENT À HER2
(KO) HER2에 특이적으로 결합하는 항체
Abstract: front page image
(EN)The present invention relates to a novel HER2 antibody for concomitant administration which is used for preventing or treating cancer. The antibody of the present invention specifically binds to HER2, which is overexpressed in cancer cells (particularly, breast cancer and gastric cancer cells), and binds to an epitope different from that to which trastuzumab binds. The antibody of the present invention has a unique sequence due to a very low homology compared with the CDR sequence of known HER2-targeting antibodies. The antibody of the present invention kills cancer cells with remarkably improved cancer cell killing ability when concomitantly administered with trastuzumab, and is thus very useful for preventing or treating cancer (particularly, breast cancer and gastric cancer). The remarkable efficacy of concomitant administration of the antibody of the present invention is considered, without wishing to be bound by theory, to be due to the antibody of the present invention binding to an epitope of HER2 different from that to which trastuzumab binds, thereby inhibiting HER2 cooperatively with trastuzumab.
(FR)Cette invention concerne un nouvel anticorps anti-HER2 à administrer de manière concomitante et qui est utilisé pour prévenir ou traiter le cancer. L'anticorps selon la présente invention se lie spécifiquement à HER2, qui est surexprimé dans les cellules cancéreuses (en particulier, les cellules du cancer du sein ou du cancer gastrique), et se lie à un épitope différent de celui auquel le trastuzumab se lie. L'anticorps selon la présente invention a une séquence unique due à une très faible homologie comparativement à la séquence CDR des anticorps ciblant HER2 connus. L'anticorps selon la présente invention détruit les cellules cancéreuses à une capacité de destruction des cellules cancéreuses très améliorée quand il est administré de manière concomitante avec le trastuzumab, et est par conséquent très utile pour prévenir ou traiter le cancer (en particulier, le cancer du sein et le cancer gastrique). La remarquable efficacité de l'administration concomitante de l'anticorps selon la présente invention est considérée, sans vouloir être lié par la théorie, comme étant due au fait que l'anticorps selon la présente invention se lie à un épitope de HER2 différent de celui auquel le trastuzumab se lie, inhibant ainsi HER2 en coopération avec le trastuzumab.
(KO)본 발명은 암 예방 또는 치료에 이용되는 병용투여용 신규한 HER2 항체에 관한 것이다. 본 발명의 항체는 암 세포(특히, 유방암 및 위암 세포)에서 과발현되는 HER2에 특이적으로 결합하는 항체로서, 트라스투주맙과는 서로 상이한 에피토프에 결합하는 항체이다. 본 발명의 항체는 종래의 HER2 타겟 항체들의 CDR 서열과 비교하여 상동성이 매우 낮아, 그 서열의 독특함이 있다. 본 발명의 항체는 트라스투주맙과 병용투여를 하는 경우, 크게 개선된 암세포 살상능으로 암세포를 살상시켜 암(특히, 유방암 및 위암)의 예방 또는 치료에 매우 유효하다. 본 발명의 항체에 의한 병용투여 효능의 우수성은, 이론에 얽매이지는 않는 범위에서(Without wishing to be bound by theory), 본 발명의 항체가 트라스투주맙과는 상이한 HER2 상의 에피토프에 결합함으로써, 트라스투주맙과 협동적으로(cooperatively) HER2를 억제하는 것으로 판단된다.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: Korean (KO)
Filing Language: Korean (KO)